Abstract
Transplantation is a life alternative for patients with organ terminal failure. This type of treatment is on the rise and in the case of refractory heart failure improves not only the life expectancy, too the quality of life. However, about 20% of the complications observed in these patients constitute complications that affect the central nervous system, some related to immunosuppressive treatment, such as infections and tumors.
We present and analyze the case of a patient who, after a heart transplant, has central nervous system tumors, in whom by post-mortem diagnosis of B-cell lymphoma.
References
White S, Hirth R, Mahíllo B. The global diffusion of organ transplantation: trends, drivers and policy implications. Bull World Health Organ. 2014;92(11):826-835. https://doi.org/10.2471/BLT.14.137653
Rosamond W, Flegal K. Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146. https://doi.org/10.1161/CIRCULATIONAHA.107.187998
Kirk R, Edwards L, Aurora P. Registry of the International Society for Heart and Lung Transplantation: Eleventh Official Pediatric Heart Transplantation Report --2008. J Heart Lung Transplant. 2008;27(9):970-77. https://doi.org/10.1016/j.healun.2008.06.016
Lund L, Edwards L, Kucheryavaya A. The registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-2013; focus theme: Age. J Heart Lung Transplant. 2013;32(10):951-64. https://doi.org/10.1016/j.healun.2013.08.006
Mehra M, Kobashigawa J, Starling R. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006. J Heart Lung Transplant. 2006;25(9):1024-42. http://dx.doi.org/10.1016/j.healun.2006.06.008
Araukua GN, Caballero EB, M. Martín JP, Rivas RM, Grille ZC, Cuenca JJ. Complicaciones neurológicas precoces tras el trasplante cardiaco. Incidencia, factores de riesgo y pronósticos. Rev Esp Cardiol. 2010;63(Supl 3):212.
Alonso-Pulpón L, Almenar L, Crespo MG. [Practice guidelines of the Spanish Society of Cardiology. Cardiac and heart-lung transplants]. Rev Esp Cardiol. 1999;52(10): 821-39.
Vallejo G, Romero C, de Vicente J. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol. 2005;56(1):87-99. http://dx.doi.org/10.1016/j.critrevonc.2004.12.011
Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F. De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. Liver Transpl.2004;11(1):89-97. http://dx.doi.org/10.1002/lt.20319
Herrero, J. I. Neoplasias postrasplante: estrategias de vigilancia y diagnóstico temprano. Gastroenterol Hepatol. 2006. 29(Supl 1):75-80.
Instituto Nacional de Salud. Informe Anual Red de Donación y Trasplantes 2013. Internet [Consultado el 23 de agosto 2016]. Disponible en: Disponible en: http://www.ins.gov.co/Kneas-de-accion/Red-Nacional-Laboratorios/Estadsticas/Forms/public.aspx
De la Cruz F, Giannitti F, Li L. Novel Polyomavirus associated with Brain Tumors in Free-Ranging Raccoons, Western United States. Emerg Infect Dis. 2013;19(1):77-84. http://dx.doi.org/10.3201/eid1901.121078
Del Valle L, White M, Khalili K. Potential Mechanisms of the Human Polyomavirus JC in Neural Oncogenesis. J Neu ropathol Exp Neurol. 2008;67(8):729-740. http://dx.doi.org/10.1097/NEN.0b013e318180e631
Swerdlow A, Higgins G, Hunt B, Thomas J, Burike M, Crawford D, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation: A cohort study of the relation to Epstein-Barr Virus1. Transplantation. 2000;69:897-904.
Cavaliere R, Petroni G, Lopes M. Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer. 2010;116(4):863-70. http://dx.doi.org/10.1002/cncr.24834
Snanoudj R, Durrbach A, Leblond V, Caillard S, Hurault De Ligny B, Noel C. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76(6):930-937. http://dx.doi.org/10.1097/01.TP.0000079253.06061.52
O'Neill B, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol. 2007;9(3):364-69. http://dx.doi.org/10.1215/15228517-2007-004
Caillard S, Lamy F, Quelen C. Epidemiology of Posttrans-plant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas. Am J Transplant. 2012;12(3):682-93. http://dx.doi.org/10.1111/j.1600-6143.2011.03896.x
Sola-Valls N, Rodríguez CN, Arcal C, Duran C, Oppenheimer F, Ribalta T, et al. Primary brain lymphomas after kidney transplantation: an under-recognized problem?. J Nephrol. 2014;27(1):95-102. http://dx.doi.org/10.1007/s40620-013-0026-z
Gelabert-González M, Castro Bouzas D, Serramito-García R. Linfomas primarios del sistema nervioso central. Neurología. 2013;28(5):283-93. https://doi.org/10.1016/j.nrl.2012.04.005
Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in nonhodgkin's lymphoma presenting as a cerebral mass lesion. Cancer. 1996;77:827-33.
Mohile N, DeAngelis L, Abrey L. The utility of body FDG PET in staging primary central nervous system lym-phoma. Neuro Oncol. 2008;10(2):223-28. http://dx.doi.org/10.1215/15228517-2007-061
Ferreri AJM. How I treat primary CNS lymphoma. Blood. 2011;118: 510-22. https://doi.org/10.1182/blood-2011-03-321349
DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined Modality Therapy for Primary CNS Lymphomas. J Clin Oncol. 1992;10(4):635-43. https://doi.org/10.1200/JCO.1992.10.4.635
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266-72. https://doi.org/10.1200/JCO.2003.09.139
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.